PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
Open Access
- 23 March 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Radiation Research
- Vol. 61 (2) , 177-186
Abstract
Proton beam therapy (PBT) combined with chemotherapy, such as cis-diamminedichloroplatinum (II) (CDDP) and 5-fluorouracil (5-FU), has been employed as an alternative approach to improve clinical outcomes. PBT has been reported to be effective against esophageal cancer. However, apart from 5-FU and CDDP, almost no other drug has been tested in combined chemotherapy with PBT. Therefore, we investigated the effects of a poly (ADP-ribose) polymerase inhibitor on enhancing proton beam effects using esophageal cancer cell lines that exhibit resistance to radiation and CDDP. Esophageal squamous cell carcinoma cell lines OE-21 and KYSE-450 were exposed to the drugs for 1 h prior to irradiation. The cell survival curve was obtained using a clonogenic assay and the sensitizing effect ratio (SER) was calculated. The clonogenic assay was used to compare the effect of multi-fractioned irradiation between 8 Gy/1 fraction (fr) and 8 Gy/4 fr. γH2AX, Rad51, BRCA1, BRCA2 and 53BP1 foci were detected via immunofluorescence. Olaparib exhibited an SER of 1.5–1.7 on PBT. The same sensitizing effect was exhibited in multi-fractioned irradiation, and the combined use increased the expression of double-strand breaks and homologous recombination-related genes in an additive manner. Such additive effects were not observed on non-homologous end joining-related genes. We demonstrated that olaparib has a high sensitizing effect on PBT in platinum- and radiation-resistant esophageal cancer cells. Our results suggest a potential clinical application of olaparib-proton irradiation (PT) against platinum- and radiation-resistant esophageal cancer.Keywords
This publication has 25 references indexed in Scilit:
- REV7 counteracts DNA double-strand break resection and affects PARP inhibitionNature, 2015
- Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancerBMC Cancer, 2015
- Targeting DNA damage response in cancer therapyCancer Science, 2014
- Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trialThe Lancet Oncology, 2013
- Biological Effects of Proton Radiation: What We Know and Don't KnowRadiation Research, 2013
- Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer researchCancer Letters, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- The role of homologous recombination in radiation-induced double-strand break repairRadiotherapy and Oncology, 2011
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- Endoscopic Biliary Drainage for Severe Acute CholangitisNew England Journal of Medicine, 1992